Kemter Elisabeth, Prückl Petra, Rathkolb Birgit, Micklich Kateryna, Adler Thure, Becker Lore, Beckers Johannes, Busch Dirk H, Götz Alexander A, Hans Wolfgang, Horsch Marion, Ivandic Boris, Klingenspor Martin, Klopstock Thomas, Rozman Jan, Schrewe Anja, Schulz Holger, Fuchs Helmut, Gailus-Durner Valérie, Hrabé de Angelis Martin, Wolf Eckhard, Aigner Bernhard
Chair for Molecular Animal Breeding and Biotechnology, and Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU, Munich, Munich, Germany.
PLoS One. 2013 Oct 24;8(10):e78337. doi: 10.1371/journal.pone.0078337. eCollection 2013.
Uromodulin-associated kidney disease (UAKD) summarizes different clinical features of an autosomal dominant heritable disease syndrome in humans with a proven uromodulin (UMOD) mutation involved. It is often characterized by hyperuricemia, gout, alteration of urine concentrating ability, as well as a variable rate of disease progression inconstantly leading to renal failure and histological alterations of the kidneys. We recently established the two Umod mutant mouse lines Umod(C93F) and Umod(A227T) on the C3H inbred genetic background both showing kidney defects analogous to those found in human UAKD patients. In addition, disease symptoms were revealed that were not yet described in other published mouse models of UAKD. To examine if further organ systems and/or metabolic pathways are affected by Umod mutations as primary or secondary effects, we describe a standardized, systemic phenotypic analysis of the two mutant mouse lines Umod(A227T) and Umod(C93F) in the German Mouse Clinic. Different genotypes as well as different ages were tested. Beside the already published changes in body weight, body composition and bone metabolism, the influence of the Umod mutation on energy metabolism was confirmed. Hematological analysis revealed a moderate microcytic and erythropenic anemia in older Umod mutant mice. Data of the other analyses in 7-10 month-old mutant mice showed single small additional effects.
尿调节蛋白相关肾病(UAKD)概括了人类常染色体显性遗传性疾病综合征的不同临床特征,该综合征已证实与尿调节蛋白(UMOD)突变有关。其特征通常为高尿酸血症、痛风、尿液浓缩能力改变,以及疾病进展速度不一,常导致肾衰竭和肾脏组织学改变。我们最近在C3H近交系遗传背景上建立了两种Umod突变小鼠品系Umod(C93F)和Umod(A227T),它们都表现出与人类UAKD患者相似的肾脏缺陷。此外,还发现了其他已发表的UAKD小鼠模型中未描述的疾病症状。为了研究其他器官系统和/或代谢途径是否作为主要或次要效应受到Umod突变的影响,我们在德国小鼠诊所对两种突变小鼠品系Umod(A227T)和Umod(C93F)进行了标准化的系统表型分析。测试了不同的基因型和不同的年龄。除了已经发表的体重、身体成分和骨代谢变化外,Umod突变对能量代谢的影响也得到了证实。血液学分析显示,老年Umod突变小鼠存在中度小细胞性和红细胞减少性贫血。对7至10月龄突变小鼠的其他分析数据显示出一些较小的额外效应。